Advaxis CEO issues statement to shareholders regarding recent common stock transition Thomas A.

Advaxis CEO issues statement to shareholders regarding recent common stock transition Thomas A. Moore, chairman and CEO of Advaxis, Inc., , the live, attenuated Listeria monocytogenes vaccine business, has issued the following statement to shareholders relating to the recent changeover to the OTCQB from the OTCBB: Dear Fellow Shareholders, Related StoriesNew vaccine applicant shows great guarantee at fighting respiratory syncytial virusResearchers reveal why malaria vaccine provides just moderate security among vaccinated childrenResearch provides prospects for new strategies to develop HIV vaccineOver the last few days, achieving the Company’s stock quotation information has been extremely difficult cheap cialis online .

In robotic prostate tumor surgery, the surgeons get higher resolution, three-dimensional field of vision and pictures that enable make exact incisions, without damaging healthy tissues. This means that the malignant cells are removed easily and likelihood of relapse are much less. Lesser Complications There are dangers of complications in every surgery. But in the entire case of robotic surgeries, complications are considerably lesser because the chances of incision attacks are greatly diminished. That is mainly because the incision is considerably little and the robotic hands that perform the surgery do not touch the incision region, reducing a patient’s susceptibility to attacks and aiding a swift and eventful recovery.